The TGF-β pathway as an emerging target for chagas disease therapy

Clinical Pharmacology and Therapeutics

Volumn 92, Issue 5, 2012, Pages 613-621

  Araujo Jorge T C ^a   Waghabi, M C ^a   Bailly, S ^b,c,d   Feige, J J ^b,c,d  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b INSERM   (France)

^c DIF   (France)

^d UNIV GRENOBLE ALPES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTISENSE OLIGONUCLEOTIDE; AP 11014; BENZNIDAZOLE; BIOLOGICAL MARKER; CYTOKINE; DIGITALIS; DISITERTIDE; DIURETIC AGENT; FRESOLIMUMAB; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEPARIN; INTERLEUKIN 6; LERDELIMUMAB; LY 2157299; LY 2382770; METELIMUMAB; NIFURTIMOX; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; SMAD2 PROTEIN; SMAD3 PROTEIN; TRABEDERSEN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 3; UNCLASSIFIED DRUG; VASODILATOR AGENT;

CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CHAGAS DISEASE; COLORECTAL CANCER; CYTOKINE RELEASE; CYTOLYSIS; DIABETIC NEPHROPATHY; DIET THERAPY; DIFFUSE SYSTEMIC SCLEROSIS; DISEASE TRANSMISSION; DRUG TARGETING; ENZYME ACTIVATION; FIBROSING ALVEOLITIS; FIBROSIS; FOCAL GLOMERULOSCLEROSIS; GLIOBLASTOMA; HEART ARRHYTHMIA; HEART DISEASE; HEART FAILURE; HEART MUSCLE FIBROSIS; HEART TRANSPLANTATION; HUMAN; HYPOSODIC DIET; IMMUNE RESPONSE; IMMUNOPROPHYLAXIS; INFECTIOUS MYOCARDIOPATHY; INFLAMMATION; KIDNEY CARCINOMA; LUNG EMBOLISM; LYMPHOCYTIC INFILTRATION; MELANOMA; MORTALITY; MYELOFIBROSIS; MYOCARDITIS; MYOCYTOLYSIS; MYOFIBROBLAST; NEOPLASM; PANCREAS CANCER; PARASITISM; PERSISTENT INFECTION; PLEURA MESOTHELIOMA; PREVALENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; REGULATORY MECHANISM; REVIEW; SCLERODERMA; SKIN FIBROSIS; SUDDEN DEATH; SYSTEMIC SCLEROSIS; TISSUE REPAIR; TREATMENT INDICATION; TRYPANOSOMA CRUZI;

ANIMALS; CHAGAS CARDIOMYOPATHY; CHAGAS DISEASE; DRUG DESIGN; GAP JUNCTIONS; HEART CONDUCTION SYSTEM; HUMANS; INFLAMMATION; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA; TRYPANOSOMA CRUZI;

EID: 84867885135     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2012.102     Document Type: Review

References (75)

1. World Health Organization. First WHO report on neglected tropical diseases 2010: working to overcome the global impact of neglected tropical diseases http://www.gsk.com/media/downloads/WHO-report-on-NTD.PDF (2011).
2. Lannes-Vieira, J., de Araújo-Jorge, T.C., Soeiro, M.d.e.N., Gadelha, P. & Corrêa-Oliveira, R. The centennial of the discovery of Chagas disease: facing the current challenges. PLoS Negl. Trop. Dis. 4, e645 (2010).
3. Rassi, A. Jr, Rassi, A. & Marin-Neto, J.A. Chagas disease. Lancet 375, 1388-1402 (2010).
4. Rassi Jr, A., Rassi, A. & Marin-Neto, J.A. Chagas heart disease: pathophysiologic mechanisms, prognostic factors and risk stratification. Mem. Inst. Oswaldo Cruz 104 (suppl. 1), 152-158 (2009).
5. Marin-Neto, J.A., Cunha-Neto, E., Maciel, B.C. & Simöes, M.V. Pathogenesis of chronic Chagas heart disease. Circulation 115, 1109-1123 (2007). (Pubitemid 46679556)
6. Bern, C. Antitrypanosomal therapy for chronic Chagas' disease. N. Engl. J. Med. 364, 2527-2534 (2011).
7. Marin-Neto, J.A. et al. The BENEFIT trial: testing the hypothesis that trypanocidal therapy is beneficial for patients with chronic Chagas heart disease. Mem. Inst. Oswaldo Cruz 104 (suppl. 1), 319-324 (2009).
8. Piez, K. & Sporn, M. Transforming Growth Factor-?s. Chemistry, Biology and Therapeutics, Vol. 593 (New York Academy of Sciences, New York, 1990).
9. Biernacka, A., Dobaczewski, M. & Frangogiannis, N.G. TGF-? signaling in fibrosis. Growth Factors 29, 196-202 (2011).
10. Dobaczewski, M., Chen, W. & Frangogiannis, N.G. Transforming growth factor (TGF)-? signaling in cardiac remodeling. J. Mol. Cell. Cardiol. 51, 600-606 (2011).
11. Massagué, J. & Gomis, R.R. The logic of TGFbeta signaling. FEBS Lett. 580, 2811-2820 (2006).
12. Moustakas, A. & Heldin, C.H. Non-Smad TGF-beta signals. J. Cell. Sci. 118, 3573-3584 (2005).
13. Bogdahn, U., Hau, P., Stockhammer, G., Venkataramana, N.K., Mahapatra, A.K., Suri, A. Targeted therapy for high-grade glioma with the TGF-beta2 inhibitor trabedersen: results of a randomized and controlled phase IIb study. Neuro. Oncol. 13, 132-142 (2011).
14. Jaschinski, F., Rothhammer, T., Jachimczak, P., Seitz, C., Schneider, A. & Schlingensiepen, K.H. The antisense oligonucleotide trabedersen (AP 12009) for the targeted inhibition of TGF-?2. Curr. Pharm. Biotechnol. 12, 2203-2213 (2011).
15. Gellibert, F. et al. Discovery of 4-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl] pyridin-2-yl}-N-(tetrahydro-2H-pyran-4-yl)benzamide (GW788388): a potent, selective, and orally active transforming growth factor-beta type I receptor inhibitor. J. Med. Chem. 49, 2210-2221 (2006).
16. Laping, N.J. et al. Inhibition of transforming growth factor (TGF)-beta1-induced extracellular matrix with a novel inhibitor of the TGF-beta type I receptor kinase activity: SB-431542. Mol. Pharmacol. 62, 58-64 (2002). (Pubitemid 34680516)
17. Petersen, M. et al. Oral administration of GW788388, an inhibitor of TGF-beta type I and II receptor kinases, decreases renal fibrosis. Kidney Int. 73, 705-715 (2008). (Pubitemid 351323246)
18. Anderton, M.J. et al. Induction of heart valve lesions by small-molecule ALK5 inhibitors. Toxicol. Pathol. 39, 916-924 (2011).
19. Prud'homme, G.J. Pathobiology of transforming growth factor beta in cancer, fibrosis and immunologic disease, and therapeutic considerations. Lab. Invest. 87, 1077-1091 (2007).
20. Araújo-Jorge, T.C., Waghabi, M.C., Soeiro, M.d.e.N., Keramidas, M., Bailly, S. & Feige, J.J. Pivotal role for TGF-beta in infectious heart disease: The case of Trypanosoma cruzi infection and consequent Chagasic myocardiopathy. Cytokine Growth Factor Rev. 19, 405-413 (2008).
21. Silva, J.S., Twardzik, D.R. & Reed, S.G. Regulation of Trypanosoma cruzi infections in vitro and in vivo by transforming growth factor beta (TGF-beta). J. Exp. Med. 174, 539-545 (1991).
22. O'Connor-McCourt, M.D. & Wakefield, L.M. Latent transforming growth factorbeta in serum. A specific complex with alpha 2-macroglobulin. J. Biol. Chem. 262, 14090-14099 (1987). (Pubitemid 17152093)
23. Araújo-Jorge, T.C. et al. Implication of transforming growth factor-beta1 in Chagas disease myocardiopathy. J. Infect. Dis. 186, 1823-1828 (2002). (Pubitemid 35463516)
24. Pérez, A.R. et al. Immunoneuroendocrine alterations in patients with progressive forms of chronic Chagas disease. J. Neuroimmunol. 235, 84-90 (2011).
25. Reis, M.M., Higuchi, M.d.e.L., Aiello, V.D. & Benvenuti, L.A. [Growth factors in the myocardium of patients with chronic chagasic cardiomyopathy]. Rev. Soc. Bras. Med. Trop. 33, 509-518 (2000).
26. Waghabi, M.C. et al. Gap junction reduction in cardiomyocytes following transforming growth factor-beta treatment and Trypanosoma cruzi infection. Mem. Inst. Oswaldo Cruz 104, 1083-1090 (2009).
27. Gutierrez, F.R., Mineo, T.W., Pavanelli, W.R., Guedes, P.M. & Silva, J.S. The effects of nitric oxide on the immune system during Trypanosoma cruzi infection. Mem. Inst. Oswaldo Cruz 104 (suppl. 1), 236-245 (2009).
28. Hawinkels, L.J. & Ten Dijke, P. Exploring anti-TGF-? therapies in cancer and fibrosis. Growth Factors 29, 140-152 (2011).
29. Santibañez, J.F., Quintanilla, M. & Bernabeu, C. TGF-?/TGF-? receptor system and its role in physiological and pathological conditions. Clin. Sci. 121, 233-251 (2011).
30. Waghabi, M.C. et al. Increased Trypanosoma cruzi invasion and heart fibrosis associated with high transforming growth factor beta levels in mice deficient in alpha(2)-macroglobulin. Infect. Immun. 70, 5115-5123 (2002).
31. Waghabi, M.C. et al. Pharmacological inhibition of transforming growth factor beta signaling decreases infection and prevents heart damage in acute Chagas' disease. Antimicrob. Agents Chemother. 53, 4694-4701 (2009).
32. Waghabi, M.C. et al. SB-431542, a transforming growth factor beta inhibitor, impairs Trypanosoma cruzi infection in cardiomyocytes and parasite cycle completion. Antimicrob. Agents Chemother. 51, 2905-2910 (2007). (Pubitemid 47206229)
33. Brand, T. & Schneider, M.D. The TGF beta superfamily in myocardium: ligands, receptors, transduction, and function. J. Mol. Cell. Cardiol. 27, 5-18 (1995).
34. Kimura, H., Takemura, H., Imoto, K., Ohshika, H. & Mochizuki, Y. Upregulation of expression of sarcoplasmic reticulum by TGF-beta 1 in cultured rat cardiac myocytes. Am. J. Physiol. 272, H2639-H2644 (1997).
35. Roberts, A.B., Roche, N.S., Winokur, T.S., Burmester, J.K. & Sporn, M.B. Role of transforming growth factor-beta in maintenance of function of cultured neonatal cardiac myocytes. Autocrine action and reversal of damaging effects of interleukin-1. J. Clin. Invest. 90, 2056-2062 (1992).
36. Khan, R. & Sheppard, R. Fibrosis in heart disease: understanding the role of transforming growth factor-beta in cardiomyopathy, valvular disease and arrhythmia. Immunology 118, 10-24 (2006).
37. Lijnen, P.J., Petrov, V.V. & Fagard, R.H. Induction of cardiac fibrosis by transforming growth factor-beta(1). Mol. Genet. Metab. 71, 418-435 (2000).
38. Schröder, D., Heger, J., Piper, H.M. & Euler, G. Angiotensin II stimulates apoptosis via TGF-beta1 signaling in ventricular cardiomyocytes of rat. J. Mol. Med. 84, 975-983 (2006). (Pubitemid 44655875)
39. Schlüter, K.D., Zhou, X.J. & Piper, H.M. Induction of hypertrophic responsiveness to isoproterenol by TGF-beta in adult rat cardiomyocytes. Am. J. Physiol. 269, C1311-C1316 (1995). (Pubitemid 3005892)
40. Pimentel, R.C., Yamada, K.A., Kléber, A.G. & Saffitz, J.E. Autocrine regulation of myocyte Cx43 expression by VEGF. Circ. Res. 90, 671-677 (2002). (Pubitemid 34640885)
41. Chanson, M. et al. Gap junctional communication in tissue inflammation and repair. Biochim. Biophys. Acta 1711, 197-207 (2005). (Pubitemid 40799294)
42. Hurst V, I.V., Goldberg, P.L., Minnear, F.L., Heimark, R.L. & Vincent, P.A. Rearrangement of adherens junctions by transforming growth factor-beta1: role of contraction. Am. J. Physiol. 276, L582-L595 (1999). (Pubitemid 29211360)
43. Dobaczewski, M. et al. Smad3 signaling critically regulates fibroblast phenotype and function in healing myocardial infarction. Circ. Res. 107, 418-428 (2010).
44. DosReis, G.A. Evasion of immune responses by Trypanosoma cruzi, the etiological agent of Chagas disease. Braz. J. Med. Biol. Res. 44, 84-90 (2011).
45. Samudio, M. et al. Local and systemic cytokine expression during experimental chronic Trypanosoma cruzi infection in a Cebus monkey model. Parasite Immunol. 21, 451-460 (1999). (Pubitemid 29401765)
46. Martin, D.L., Postan, M., Lucas, P., Gress, R. & Tarleton, R.L. TGF-beta regulates pathology but not tissue CD8+ T cell dysfunction during experimental Trypanosoma cruzi infection. Eur. J. Immunol. 37, 2764-2771 (2007). (Pubitemid 47578295)
47. Zhang, L. & Tarleton, R.L. Characterization of cytokine production in murine Trypanosoma cruzi infection by in situ immunocytochemistry: lack of association between susceptibility and type 2 cytokine production. Eur. J. Immunol. 26, 102-109 (1996).
48. de Oliveira, F., Araújo-Jorge, T., de Souza, E., de Oliveira, G., Degrave, W., Feige, J. Oral administration of GW788388, an inhibitor of transforming growth factor-beta signaling, prevents heart fibrosis in Chagas disease. PLoS Negl. Trop. Dis. 6, e1696 (2012).
49. Oz, H.S., Hughes, W.T., Thomas, E.K. & McClain, C.J. Effects of immunomodulators on acute Trypanosoma Cruzi infection in mice. Med. Sci. Monit. 8, BR208-BR211 (2002). (Pubitemid 34694641)
50. Medeiros, G.A. et al. Treatment of chronically Trypanosoma cruzi-infected mice with a CCR1/CCR5 antagonist (Met-RANTES) results in amelioration of cardiac tissue damage. Microbes Infect. 11, 264-273 (2009).
51. Pérez, A.R., Fontanella, G.H., Nocito, A.L., Revelli, S. & Bottasso, O.A. Short treatment with the tumour necrosis factor-alpha blocker infliximab diminishes chronic chagasic myocarditis in rats without evidence of Trypanosoma cruzi reactivation. Clin. Exp. Immunol. 157, 291-299 (2009).
52. Cutrullis, R.A., Poklépovich, T.J., Postan, M., Freilij, H.L. & Petray, P.B. Immunomodulatory and anti-fibrotic effects of ganglioside therapy on the cardiac chronic form of experimental Trypanosoma cruzi infection. Int. Immunopharmacol. 11, 1024-1031 (2011).
53. Iosa, D., Massari, D.C. & Dorsey, F.C. Chagas' cardioneuropathy: effect of ganglioside treatment in chronic dysautonomic patients-a randomized, double-blind, parallel, placebo-controlled study. Am. Heart J. 122, 775-785 (1991).
54. Mitelman, J., Gimenez, L., Aparicio, N.J. & Cortelezzi, M. Long-term treatment of chronic chagasic cardioneuropathy with a mixture of gangliosides: effect on evolution of circulating antiGM1 antibodies. J. Cardiol. 34, 189-197 (1999). (Pubitemid 29510334)
55. Adesse, D. et al. Gap junctions and chagas disease. Adv. Parasitol. 76, 63-81 (2011).
56. de Carvalho, A.C. et al. Gap junction distribution is altered between cardiac myocytes infected with Trypanosoma cruzi. Circ. Res. 70, 733-742 (1992).
57. Zhang, Y., Kanter, E.M. & Yamada, K.A. Remodeling of cardiac fibroblasts following myocardial infarction results in increased gap junction intercellular communication. Cardiovasc. Pathol. 19, e233-e240 (2010).
58. Ramos-Mondragón, R., Galindo, C.A. & Avila, G. Role of TGF-beta on cardiac structural and electrical remodeling. Vasc. Health Risk Manag. 4, 1289-1300 (2008).
59. Severs, N.J., Bruce, A.F., Dupont, E. & Rothery, S. Remodelling of gap junctions and connexin expression in diseased myocardium. Cardiovasc. Res. 80, 9-19 (2008).
60. Calzada, J.E., Beraún, Y., González, C.I. & Martín, J. Transforming growth factor beta 1 (TGFbeta1) gene polymorphisms and Chagas disease susceptibility in Peruvian and Colombian patients. Cytokine 45, 149-153 (2009).
61. Zicker, F., Smith, P.G., Netto, J.C., Oliveira, R.M. & Zicker, E.M. Physical activity, opportunity for reinfection, and sibling history of heart disease as risk factors for Chagas' cardiopathy. Am. J. Trop. Med. Hyg. 43, 498-505 (1990).
62. Costa, G.C. et al. Functional IL-10 gene polymorphism is associated with Chagas disease cardiomyopathy. J. Infect. Dis. 199, 451-454 (2009).
63. Lescure, F.X. et al. Chagas disease: changes in knowledge and management. Lancet Infect. Dis. 10, 556-570 (2010).
64. Euler-Taimor, G. & Heger, J. The complex pattern of SMAD signaling in the cardiovascular system. Cardiovasc. Res. 69, 15-25 (2006). (Pubitemid 41814808)
65. Pokharel, S. et al. Increased myocardial collagen content in transgenic rats overexpressing cardiac angiotensin-converting enzyme is related to enhanced breakdown of N-acetyl-Ser-Asp-Lys-Pro and increased phosphorylation of Smad2/3. Circulation 110, 3129-3135 (2004). (Pubitemid 39492009)
66. Koitabashi, N. et al. Pivotal role of cardiomyocyte TGF-? signaling in the murine pathological response to sustained pressure overload. J. Clin. Invest. 121, 2301-2312 (2011).
67. Bonafoux, D. & Lee, W.C. Strategies for TGF-beta modulation: a review of recent patents. Expert Opin. Ther. Pat. 19, 1759-1769 (2009).
68. Frazier, K. et al. Inhibition of ALK5 signaling induces physeal dysplasia in rats. Toxicol. Pathol. 35, 284-295 (2007). (Pubitemid 46393081)
69. Mallat, Z. et al. Inhibition of transforming growth factor-beta signaling accelerates atherosclerosis and induces an unstable plaque phenotype in mice. Circ. Res. 89, 930-934 (2001). (Pubitemid 34627899)
70. Muratore, C.A. & Baranchuk, A. Current and emerging therapeutic options for the treatment of chronic chagasic cardiomyopathy. Vasc. Health Risk Manag. 6, 593-601 (2010).
71. Benaim, G. et al. Amiodarone has intrinsic anti-Trypanosoma cruzi activity and acts synergistically with posaconazole. J. Med. Chem. 49, 892-899 (2006). (Pubitemid 43221637)
72. Paniz-Mondolfi, A.E., Pérez-Alvarez, A.M., Lanza, G., Márquez, E. & Concepción, J.L. Amiodarone and itraconazole: a rational therapeutic approach for the treatment of chronic Chagas' disease. Chemotherapy 55, 228-233 (2009).
73. Card, J.W., Racz, W.J., Brien, J.F. & Massey, T.E. Attenuation of amiodaroneinduced pulmonary fibrosis by vitamin E is associated with suppression of transforming growth factor-beta1 gene expression but not prevention of mitochondrial dysfunction. J. Pharmacol. Exp. Ther. 304, 277-283 (2003). (Pubitemid 36008939)
74. Adesse, D., Azzam, E.M., Meirelles, M.d.e.N., Urbina, J.A. & Garzoni, L.R. Amiodarone inhibits Trypanosoma cruzi infection and promotes cardiac cell recovery with gap junction and cytoskeleton reassembly in vitro. Antimicrob. Agents Chemother. 55, 203-210 (2011).
75. Gordon, J. & Kopp, J.B. Off the beaten renin-angiotensin-aldosterone system pathway: new perspectives on antiproteinuric therapy. Adv. Chronic Kidney Dis. 18, 300-311 (2011).